



GP 1614 #4 (R) 7/1/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

THE APPLICATION OF: Carter et al. : CASE NO.: PH-7268
SERIAL NO.: 10/027,505 : ART UNIT: 1614
FILED: December 20,2001: EXAMINER: Unknown

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

INFORMATION DISCLOSURE STATEMENT

RECEIVED

JUN 13 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH. UNIT: 1600/2900

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (X) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below.
- () The fee of **\$240.00** as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of **\$130.00** as set forth in §1.17(i)(1)

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

Respectfully submitted,

Mary K. VanAtten

Mary K. VanAtten
Attorney for Applicants
Registration No. 39,408
Telephone: 302-467-5268

DATE: June 6, 2002
Bristol-Myers Squibb Company
P. O. Box 4000
Princeton, NJ 08543-4000



Certificate of Mailing under 37 CFR 1.8

In the Application of: **Carter et al.**

CASE NO.: **PH-7268**

APPLICATION NO.: **10/027,505**

GROUP ART UNIT: **1614**

FILED: **DECEMBER 20, 2001**

EXAMINER: **UNKNOWN**

FOR: **DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY**

I hereby certify that this correspondence, a Information Disclosure Statement is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on June 7, 2002
Date

RECEIVED

JUN 13 2002

TECH CENTER 1600/2900

Denise Bierlein

Signature

Denise Bierlein

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.